ACCESS TO MEDICINES

FORUM

5 December 2022

Scotland House, Brussels

JOIN THE DEBATE!

Share your questions and comments with us throughout the day.

#Access2Medicines

Co-funded by the
Health Programme of
the European Union

The European Public Health Alliance has received funding under an operating grant from the European Union's Health Programme (2021-2027). The content of this publication represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

ABOUT EPHA'S ACCESS TO MEDICINES ADVOCACY

The access to medicines (A2M) Forum is a yearly event organised by EPHA to foster a meaningful and inclusive dialogue on access to medicines and pharmaceutical policies in Brussels and beyond.

The 2022 EPHA A2M Forum is the first edition after the pandemic. It follows a period of increased political attention for access to medicines, which has brought high expectations but limited results in terms of equitable access to affordable medicines at global, EU and national levels.



WELCOME TO THE 5TH EPHA ACCESS TO MEDICINES FORUM!

While the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it has also underscored the need for more balance, transparency, and accountability in the pharmaceutical sector.

The Forum coincides with the preparation by the European Commission of a proposal for the revision of the EU pharmaceutical legislation and the EU legislation on medicines for children and rare diseases, which bring unique opportunities to restore the balance and ensure affordable access to quality, safe, innovative, and effective medicines at EU level. This major revision is taking place against a background of increased focus on addressing antimicrobial resistance, global negotiations on a potential Pandemic Treaty, and the multi-stakeholder platform recently launched by the WHO Europe to facilitate dialogue on better access to high-cost medicines.

EPHA, its members and partner organizations in our hosted European Alliance for Responsible R&D and Affordable Medicines have been centre stage in contributing to policy debates, forging new coalitions, highlighting the public health and patient-centric perspectives, and advocating for more inclusive and balanced discussion around medicines policies.

The 2022 edition of EPHA's A2M Forum will provide a unique opportunity for further exchanges and cross-fertilization of ideas between different stakeholders (patients, healthcare professionals, payers medicine agencies, European policymakers, health law experts) on key A2M issues.

5th EPHA Universal Access and Affordable Medicines Forum

Equal access to affordable medicines: Global, EU and National voices

09:00-09:15	REGISTRATION AND COFFEE
09:15-09:45	WELCOME AND SETTING THE SCENE • Milka Sokolović — Director General, European Public Health Alliance (EPHA) @EPHA_EU @milkasklvc • Sylvain Giraud — Head of Unit at DG SANTE, European Commission @EU_Commission @GiraudSylvain • Els Torreele — Policy Associate, UCL Institute for Innovation & Public Purpose (IIPP) @IIPP_UCL @ElsTorreele
09:45-11:00	EU JOINT PROCUREMENT & CROSS-BORDER COLLABORATIONS: WHAT ELSE CAN BE DONE TO IMPROVE ACCESS AND AFFORDABILITY? Moderated by Stephanie Kohl, European Association of Hospital Pharmacists • Marc Botenga — MEP, European Parliament @Europarl_EN @BotengaM • Olivier Girard — Head of Unit HERA, European Commission @EU_Commission @EC_HERA • Momir Radulović — Director, Slovenian Medicines Agency @AgencijaJAZMP • Charlotte Roffiaen — European Affairs Advisor, France Assos Sante @Fr_Assos_Sante @EU4Ublog • Maja Graf— Markets Director, Medicines for Europe @medicinesforEU
11:00-11:30	COFFEE BREAK
11:30-12:30	TRANSPARENCY OF PHARMACEUTICAL R&D COSTS: WHAT, WHO AND HOW? Moderated by Ella Weggen, Wemos • Nora Franzen — European Fair Pricing Network (EFPN) #EFPNforMeds • Nicola Magrini — Director, Italian Medicines Agency (AIFA) @Aifa_ufficiale

- Tilly Metz — MEP, European Parliament
  @Europarl_EN @MetzTilly
- Els Torreele — Policy Associate, UCL Institute for Innovation & Public Purpose (IIPP)
  @IIPP_UCL @ElsTorreele

12:30-13:30 LUNCH

13:30-14:30 CAN A MULTI-STAKEHOLDER PLATFORM SUPPORT AFFORDABLE ACCESS TO MEDICINES?

Moderated by Alba Gil, European Public Health Alliance (EPHA)

- Sarah Garner — Senior Policy Advisor, World Health Organization - Europe (WHO)
  @WHO_Europe @drsarahgarger
- Simone Boselli — Public Affairs Director, Eurordis
  @eurordis
- Yannis Natsis — Director, European Social Insurance Platform (ESIP)
  @ESIP_EU @YNatsis
- Ward Rommel — Researcher, Kom op tegen Kanker, Access to Medicines Taskforce, European Cancer Leagues (ECL)
  @WardRommel @CancerLeagues @komop_tgkanker
- Jaume Vidal — Senior Policy Advisor, Health Action International (HAI)
  @HAImedicines @OnadaExpansiva

14:30-15:00 COFFEE BREAK

15:00-16:30 TOWARDS GLOBAL ACCESS TO NEW & EFFECTIVE ANTIBIOTICS: THE ROLE OF THE EU

Moderated by Rosa Castro, European Public Health Alliance (EPHA)

- Kerstin Åkerfeldt — Policy Expert, ReAct Europe
  @reactgroup @KAkerfeldt
- Malin Grape — Swedish AMR Ambassador
- Massimo Florio — University of Milan
- Anca Toma — Executive Director, European Patients' Forum (EPF)
  @eupatientsforum @ Anca4health

16:30-16:45 CLOSING REMARKS

WELCOME AND SETTING THE SCENE

09:15-09:45

Milka Sokolović

Director General, European Public Health Alliance (EPHA)
@EPHA_EU @milkasklvc

As Director General of EPHA, the European Public Health Alliance, Dr Milka Sokolović supports the organisation's relentless work to improve health, and strengthen the voice of public health in Europe.

She started her career in Belgrade's Institute for Molecular Genetics and Genetic Engineering, studying the expression and function of human SOX genes. The majority of her 15 academic years, however, took place at the University of Amsterdam, where she studied the intermediary metabolism of starvation and obesity, and taught subjects like medical biochemistry, DNA technology, metabolism and genomics.

Moving to Brussels, to the European Food Information Council, she led the Department of Food & Health Science for eight years, translating the complexity of science into "human" language, to help people make sense and use of it.

For five years Milka also acted as a Director of the Advanced Programme of the European Nutrition Leadership Platform, supporting food and nutrition professionals in making a lasting difference in the European public health landscape. Milka holds a degree in Biology from the University of Belgrade, and a PhD in Medicine from the University of Amsterdam.

Sylvain Giraud

Head of Unit at DG SANTE, European Commission
@EU_Commission @GiraudSylvain

Sylvain Giraud is the Head of Unit "Medical products: quality, safety and innovation" in the Directorate General for Health and Food Safety of the European Commission (DG SANTE). The unit is in charge of EU level policy developments on quality, availability and affordability of medicines and supervises important aspects of the implementation of EU legislation, the implementation of the Pharmaceutical Strategy for Europe and the coordination of international cooperation on medicines policy. In previous Head of Unit positions in DG SANTE in the last 10 years Sylvain has been dealing with Health Systems, global health and EU health policy coordination.

Els Torreele

Policy Associate, UCL Institute for Innovation & Public Purpose (IIPP)
@IIPP_UCL @ElsTorreele

Els Torreele is a medical innovation and socio-economic justice researcher and advocate, focusing on transforming medical R&D to address priority health needs and ensure equitable access to knowledge and technologies. A Bio-Engineer and PhD from Brussels University (VUB), for over 20 years she has combined medical R&D work, policy research, and advocacy at Brussels University, Médecins Sans Frontières, Drugs for Neglected Diseases initiative, Open Society Foundations and is now Visiting Fellow at the Institute for Innovation and Public Purpose, University College London. A recent Rockefeller Bellagio Centre resident (March 2022), she's an Honorary Science Fellow at the VUB, author on over 50 international journal publications, and regular contributor to the societal debate through media and social media.

EU JOINT PROCUREMENT & CROSS-BORDER COLLABORATIONS: WHAT ELSE CAN BE DONE TO IMPROVE ACCESS AND AFFORDABILITY?

09:45-11:00

Reflecting on the experience during the COVID-19 pandemic and monkeypox outbreak, this session will dig into the future of EU joint procurement for medicines and vaccines. What is needed for EU joint procurement to support access to affordable medicines? What can we learn from cross-border collaborations, including Beneluxa to enhance access to affordable medicines? Could joint procurement be used to help in other areas such as medicines for rare diseases?

Stephanie Kohl

Policy & Advocacy Officer,
European Association of Hospital Pharmacists (EAHP)
@EAHPtweet @KohlSteph1

The European Association of Hospital Pharmacists (EAHP) represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. In her capacity as Policy & Advocacy Officer, Stephanie is responsible for all of EAHP's policy engagements and coordinates EAHP's Special Interest Groups. She joined the Association in 2017 and works on all topics relevant to the hospital pharmacy profession. Key topics include but are not limited to medicines shortages, antimicrobial resistance, procurement, digital health, medical devices and access to medicines. Prior to joining EAHP, she was a legal consultant responsible for examining the implementation of EU legislation in Member States.

Marc Botenga

MEP, European Parliament
@Europarl_EN @BotengaM

Marc Botenga is a Left MEP, of the Workers Party of Belgium. Before his term as an MEP, he was active in global health activism. During the COVID-19 pandemic, he became a strong advocate and campaigner in favour of transparency in regard to vaccine procurement, the TRIPS-Waiver and lifting IP on health technologies in order tpo make vaccines a global public good, notably via the "No profit on the pandemic" campaign.

Olivier Girard

Head of Unit HERA, European Commission
@EU_Commission @EC_HERA

Olivier has been Head of Unit for Medical Counter Measures within HERA since July 2022. He joined the Commission in 2003, after beginning his career in London and Paris as a qualified French and UK Avocat/ Solicitor. After having worked on financial services, single market and industry policies in various functions within the Commission, his last position before joining HERA was Head of unit in the Secretariat-General of the Commission in charge of digital transition, industrial policy and research and innovation.

Momir Radulović

Director, Slovenian Medicines Agency
@AgencijaJAZMP

Momir Radulović leads the Slovenian Medicines and Medical Devices Agency since Dec 2018. He is a member of the European Medicines Agency Management Board, the EC Pharmaceutical Committee, the Heads of Medicines Management Group, the EU Network Training Centre Steering Group, and a member of Oslo Medicines Initiative Scientific Program Committee.

His previous work experience includes Hospital, Community Pharmacy and Pharma industry, where he focused on oncology medicines, HIV, vaccines, and in vitro diagnostics. By living in 6 and working in 10 different countries with diverse health systems and cultural environments and through different work areas, projects, and assignments he has learned to adapt swiftly to changes and to seize the opportunities that those can offer.

Charlotte Roffiaen

European Affairs Advisor, France Assos Sante
@Fr_Assos_Sante @EU4Ublog

Charlotte Roffiaen is a trained lawyer. She has been involved in health advocacy since 2001, when she contributed to the creation and the development of Active Citizenship Network. Charlotte now works as a consultant and advises organisations representing patients and health care users – such as France Assos Santé – on their advocacy strategies, with a focus on access to medicines. France Assos Santé, which counts about 100 member associations and is an active member of EPHA, defends the rights of all patients and citizens to a quality health care, both in France and at EU level.

Maja Graf

Markets Director, Medicines for Europe
@medicinesforEU

Maja Graf is an Associate Director Policy & Market Access for Medicines for Europe, a trade association representing the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. In her role, she focuses on issues such as equitable access to affordable treatments across Europe, sustainable pharmaceutical markets for off-patent medicines and innovation throughout the medicines life cycle, in the form of Value Added Medicines. She holds the Master of Sciences of Pharmacy degree obtained from Faculty of pharmacy, University of Ljubljana. Before joining Medicines for Europe, she worked in the pharmaceutical industry. Medicines for Europe is a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.

TRANSPARENCY OF PHARMACEUTICAL R&D COSTS: WHAT, WHO AND HOW?

11:30-12:30

Current studies show significant differences in the range of estimated R&D costs for new medicines. While the 2019 World Health Assembly resolution WHA72.8 called for improved transparency of markets for medicines, asymmetries of information between the private and public sector affect drug pricing negotiations. This session will discuss potential solutions to improve transparency of pharmaceutical R&D costs.

What type of pharmaceutical R&D transparency do we need? What should be disclosed and to whom? What are the different national experiences in implementing these obligations? Could a disclosure obligation for industry R&D costs help to bring more affordable medicines into the market?

Ella Weggen

Senior Global Health Advocate, Wemos

@helse_og_omsorg

Ella coordinates the international consortium COVID-19 Innovations for All (CIFA), that encourages the sharing of intellectual property rights, know-how and technology needed for the production of medical products against COVID-19, such as vaccines and medicines. CIFA's goal is maximization of the production capacity of these products, so everyone in the world gets equal access to them. This is vital in ending the corona pandemic.

Ella has extended experience in influencing policy of the Dutch government, the European Union and the World Health Organization on global health issues. She worked at the Dutch Ministry of Foreign Affairs as an intern, and at the Political Affairs department of Amnesty International in the Netherlands. Thanks to her working experience as an assistant for four years in the European Parliament in Brussels, she has extensive knowledge of how (EU level) politics work. Ella studied Political Science and Public International and European Law in Amsterdam.

Nora Franzen

European Fair Pricing Network (EFPN)

#EFPNforMeds

Nora Franzen completed with distinctions (cum laude) a PhD in Health Economics at the Netherlands Cancer Institute/University of Twente and a MSc in Health Science at Maastricht University. She holds a BA from the University of California, Berkeley. Previously to her academic career, she has worked for four years as a Senior Research Analyst for the strategic management consulting firm McKinsey & Co.

Nora Franzen's research interests lie in health economics and healthcare system research with a focus on innovation. During her PhD project, she conducted research on innovative payment strategies to increase the affordability of anticancer medicines. In one of her projects, she conducted an economic laboratory experiment on the effect of price transparency and R&D cost transparency on European pharmaceutical prices.

Currently, she holds a postdoctoral position at the Netherlands Cancer Institute/European Fair Pricing Network in the group of Prof. van Harten & Dr. Retèl. Her research is focused on topics of affordability and accessibility of medicines in oncology. She combines quantitative and qualitative research to increase the evidence base in the field (multi-agent modeling, scenario analysis, surveys, decision analysis, economic experimentation). Moreover, she is engaged in a large EU Horizon project to explore real world data methods in health technology assessment.

Nicola Magrini

Director of the Italian Medicines Agency (AIFA)

@Aifa_ufficiale

Nicola Magrini, a medical doctor with a specialty in Clinical Pharmacology, has 20 years' experience in drug evaluation, evidence synthesis, guideline development and pharmaceutical policies.

He started his career in academia at the University of Bologna and at Mario Negri Institute working in clinical trials, metanalysis, and pharmacoepidemiology. A founder member of the Italian Cochrane Centre in 1994, he established a NHS Centre on knowledge brokering and guideline development (NHS CeVEAS, Centre for the evaluation of the effectiveness of Health care) in Modena, Italy from 1999 till 2012.

Director of the WHO Collaborating Centre for Evidence-Based Research Synthesis and Guideline Development from 2008 until 2014. He has a special interest in research ethics and active participation in clinical trials. He was scientist at WHO Geneva as Secretary of the Expert Committee on the Selection and Use of Essential Medicines from 2014 to 2020. He is currently (from March 2020) Director General of AIFA, the Italian Medicines Agency.

Tilly Metz

MEP, European Parliament
@Europarl_EN @MetzTilly

Tilly Metz is a Luxembourgish Member of the European Parliament since July 2018.

She represents the Greens/EFA Group in the Committees on Environment, Public Health and Food Safety, Transport and Tourism, and Agriculture and Rural Development as well as the Special Committee on the COVID-19 pandemic. She also chairs the Delegation for Relations with Central American Countries.

Health and health care are among her core issues: she is the Health coordinator of the Greens/EFA Group in the European Parliament and represented them in the negotiations on the extension of the mandate of the European Medicines Agency and around the Pharmaceutical Strategy. She is also Vice-President of the Intergroup on People with Disabilities and advocates for the treatment of rare diseases.

CAN A MULTI-STAKEHOLDER PLATFORM SUPPORT AFFORDABLE ACCESS TO MEDICINES?

13:30-14:30

The Oslo Medicines Initiative (OMI) was launched in 2020 as a collaboration between the WHO European Region and the Government of Norway. In September 2022, Member States gave a mandate to the WHO Europe to launch a multi-stakeholder platform between different stakeholders including the public and private sectors, patients, and civil society to co-create solutions for improving access to novel (high priced) medicines.

This session will explore what is planned and what will be needed for the multi-stakeholder platform recently launched by the WHO Europe to contribute to better access to (affordable) new medicines. How should discussions be organized? Which topics should be discussed (e.g., joint procurement, transparency, pricing & reimbursement, etc.)? How will the platform ensure a level playing field among non-state actors?

Alba Gil

Junior Policy Manager for Healthcare Delivery,
European Public Health Alliance (EPHA)
@EPHA_EU @AlbaGilCa

As Junior Policy Manager Alba supports activities of the healthcare delivery, health systems, and economy cluster activities, including the work of the European Alliance for Responsible R&D and Affordable Medicines.

Alba holds a BA in Law and Political Sciences by Carlos III University of Madrid (ES), and a MA in European Studies by the University of Maastricht (NL). She has also conducted research on the Regulation 1169/2011 on Food Information to Consumers regarding both food stakeholders and allergens labelling. She started her adventure in Brussels as trainee in the European Parliament, followed by a EIT Food Fellowship in EuroFIR and a great experience in Quisper, working in food composition and Open Science.

Sarah Garner

Senior Policy Advisor, World Health Organization - Europe (WHO)
@WHO_Europe @drsarahgarger

Sarah Garner PhD, BPharm is currently the Senior Policy Advisor, Access to Medicines and Health Products, WHO Regional Office for Europe. Sarah is a pharmacist specializing in global access issues and she is responsible for the strategic planning and delivery of policy dialogue and technical support to improve patient access. This includes pharmaceutical systems strengthening, regulation, selection, HTA, pricing and procurement. Sarah is the technical lead for the WHO/Europe Access to Novel Medicines Platform and has led policy work-packages of public private research partnerships funded by the EU Innovative Medicines Initiative.

Her previous roles have included the Coordinator for the 'Innovation, Access and Use' Team in the Essential Medicines and Health Products Department at WHO HQ and the Associate Director for Science Policy and Research at the UK's National Institute for Health and Care Excellence (NICE), and Pharmacist Lead for the UK Government's Special Advisory Committee on Antimicrobial Resistance.

Simone Boselli

Public Affairs Director, Eurordis
@eurordis

Since joining EURORDIS in 2017 as a member of the EURORDIS Policy and Advocacy team, Simone has worked to advance policy solutions to the development and access to therapies for rare diseases, with a focus on reducing delays and inequalities, on the underlying challenges in the field of the value assessment, pricing and reimbursement of orphan medicines.

Yannis Natsis

Director, European Social Insurance Platform (ESIP)
@ESIP_EU @YNatsis

The European Social Insurance Platform (ESIP) is an umbrella organisation bringing together 45 national statutory social security institutions from 18 countries. ESIP is the voice of social protection and security in Europe or as Yannis puts it one of Europe's truest treasures. He has more than 10 years of experience in EU advocacy and policymaking.

Prior to joining ESIP in February 2022, he led the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). In May 2019, he was appointed by EU Member States to the Management Board of the European Medicines Agency (EMA), a position he held until December 2021. Additionally, Yannis has been a Board member of the European Health Forum Gastein (EHFG), the leading EU health policy platform since 2018. Yannis previously worked for the TransAtlantic Consumer Dialogue (TACD) focusing on health and pharmaceutical policies. From 2006-2010, he was an investigative reporter for Greece's award-winning TV news programme "Fakeli" and a contributor to one of Greece's most respected dailies "Kathimerini". He has a Master's degree in International Conflict Analysis from the University of Kent, UK and a Bachelor's degree in European Studies from Pantion University of Social and Political Sciences, Athens, Greece. A Greek national, he is fluent in Greek, English and French.

Ward Rommel

Researcher, Kom op tegen Kanker, Access to Medicines Taskforce, European Cancer Leagues (ECL)

@WardRommel @CancerLeagues @komop_tgkanker

Ward Rommel is research and advocacy officer at the Flemish Cancer Society '***Kom op tegen Kanker***'. This independent NGO plays a leading role in the fight against cancer in Flanders. In recent years, Ward has advocated for access to fairly priced medicines and for the establishment of reference centers for the treatment of patients with rare and complex tumours. Since 2019, he is chair of the ECL Access to Medicines Task Force. ECL, the Association of European Cancer Leagues, is a non-profit, pan-European umbrella organisation representing 31 national and regional cancer societies working in the areas of cancer prevention, tobacco control, patient support and access to medicines. The aim of the ECL Access to Medicines Task Force is to make safe and effective medicines available to all cancer patients in Europe. Since 2016 the Task Force is an important voice in the European medicines policy debate. It has published policy papers on fair pricing, Europe's Pharmaceutical Strategy, Europe's Beating Cancer Plan and cross-border collaboration initiatives in the healthcare space (see Task Force Advocacy | Association of European Cancer Leagues - ECL).

Jaume Vidal

Jaume Vidal — Senior Policy Advisor, Health Action International (HAI)

@HAImedicines

Jaume Vidal is a Political Science graduate, specialising in International Relations, with a 20-year strong career on public health issues with special focus on access to health technologies. His professional experience includes roles in various international organisations, think tanks and non-government organisations.Jaume leads HAI's advocacy and campaign work on access to medicines in Europe, including pricing, transparency, trade and research and development. He is also responsible for following up and interacting with World Health Organization bodies and initiatives.

TOWARDS GLOBAL ACCESS TO NEW & EFFECTIVE ANTIBIOTICS: THE ROLE OF THE EU

15:00–16:30

While antimicrobial resistance is on the rise, the scarcity of new antibiotics and a currently dry clinical pipeline is leaving the world with a few options to combat multiple resistant germs. Incentives to stimulate the development of new antibiotics are currently being discussed at global level as well as in the EU in the context of the revision of the EU pharmaceutical legislation, the development of HERA activities and other innovative ideas such as the creation of a European Biomedical Infrastructure. This panel will address the challenges of creating incentives for the development of new and effective antibiotics while guaranteeing access and antibiotic stewardship.

What are the best policy options available to spur the development of new and effective antibiotics? How can consistency across EU policies as well as with global cooperation be built?

Rosa Castro

Senior Policy Manager for Healthcare Delivery, European Public Health Alliance (EPHA)
@EPHA_EU @RosaCastroB

Dr Rosa Castro is the Senior Policy Manager for Healthcare Delivery and EPHA Networks' Coordinator. Among other activities, she represents EPHA in the Patients' and Consumers Working Party at the European Medicines Agency (EMA) and on the European Health Emergency Preparedness and Response Authority (HERA) Civil Society Advisory Forum. She obtained a PhD in European Law and Economics, and an MA in Bioethics and Science Policy, wrote a book and articles on patents and health, was a postdoctoral Fellow at the European University Institute, and at Duke University, USA, and lectured on intellectual property and health law. Before joining EPHA in 2021, she also worked in Brussels as Senior Scientific Policy Officer at the Federation of European Academies of Medicine (FEAM) and as Senior Policy Advisor at a public policy consultancy.

Kerstin Åkerfeldt

Policy Expert, ReAct - Action on Antibiotic Resistance
@reactgroup @KAkerfeldt

As a Policy Expert Kerstin Åkerfeldt supports the development of ReAct's policy positions, recommendations and advocacy strategies towards relevant stakeholders and provides input to debates at global, regional and national level on antibiotics resistance. Her work focuses on Research & Development and access to medicines, global governance, sustainable financing for health and strengthening of health systems. Before joining ReAct, she worked 20 years in different capacities for MSF including as a Health Policy- and Advocacy Advisor and a liaison officer towards the Global Fund to fight AIDS, Tuberculosis and Malaria. She also has experience from health policy and advocacy work in low resource settings. Kerstin holds a Master's degree in International Studies from Uppsala University.

Malin Grape

Ambassador on Antimicrobial Resistance,
Ministry of Health and Social Affairs, Sweden

In her previous position as Deputy Head of Department for Communicable Disease Control and Health Protection and Head of Unit for Antibiotics and Infection Control at the Public Health Agency of Sweden she was responsible for national coordination and international cooperation on antimicrobial resistance and healthcare associated infections. Dr Grape is a licensed pharmacist and holds a PhD in medical science from the Karolinska Institute. Her research and previous professional experience span a broad field from clinical microbiology to global health. Dr Malin Grape has been the chair of the national sector-wide coordinating mechanism on antibiotic resistance including 22 governmental agencies as well as director of a WHO Collaboration Centre for antimicrobial resistance containment. She was a member of the programme committee of the national research programme on antibiotic resistance and council member of the National Council for Patient Safety.

Massimo Florio

University of Milan

Massimo Florio is Professor of Public Economics, University of Milan, Jean Monnet Centre of Excellence "***The Impact of European Union Research and Innovation Policy upon Services of General Interest***" and formerly Head of the Economics Department. His research interests include privatisation and public enterprise, social cost benefit analysis of public investment, EU regional and industrial policy, economics of science and innovation. He has coordinated for over twenty years editions of the European Commission's "***Guide of cost-benefit analysis of investment projects***" and led evaluation studies for the EC, EIB; EP, OECD, CERN and Italian Space Agency. His book "***Investing in Science***" was published in 2019. A new book on the "***Privatisation of Knowledge***" deals with social justice and EU policies in biomedical research, climate change and big data governance. He has recently led the STOA study "***European pharmaceutical research and development: Could a public infrastructure overcome market failures?***"

Anca Toma

Executive Director, European Patients' Forum (EPF)
@eupatientsforum @ Anca4health

Anca Toma joined EPF as Executive Director in March 2022. Her career started in the Romanian EU accession negotiations team, continued as a consultant in a public affairs and communications agency in Brussels, followed by ten years in Smoke Free Partnership, a European coalition of NGOs working to advance tobacco control for cancer and NCD prevention. Anca has over 15 years of experience in European health policy working in policy advocacy, strategic communications, developing and coordinating successful pan-European advocacy campaigns, and leading her team and organisation. Anca is a political science graduate of the University of Bucharest and holds a masters in European politics and administration from the College of Europe.

ACCESS TO MEDICINES FORUM

5 December 2022
Scotland House, Brussels

#Access2Medicines

European Public Health Alliance (EPHA) AISBL
Rue de Trèves 49-51, 1040 Brussels (B) • +32 02 230 30 56
www.epha.org • epha@epha.org @EPHA_EU
Transparency Register Number: 18941013532-08